Storia della carriera di Gavin B. Samuels
Precedenti posizioni note di Gavin B. Samuels
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 01/01/2007 | 23/09/2010 |
| PFIZER, INC. | Corporate Officer/Principal | - | - |
Formazione di Gavin B. Samuels
| University of the Witwatersrand | Doctorate Degree |
| University of New England (Australia) | Masters Business Admin |
| Monash University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Australia | 3 |
| Sud Africa | 2 |
Posizioni
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Settori
| Consumer Services | 4 |
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Borsa valori
- Insiders
- Gavin B. Samuels
- Esperienza
